Nymox’s Hyperplasia Drug Reduces Incidence of Nocturia

Nymox Pharmaceutical has announced that results from a new multi-center US Phase II study showed evidence that the company’s proprietary drug NX-1207, can markedly reduce the incidence of nighttime urination or nocturia, a symptom associated with benign prostatic hyperplasia.

After 90 days, subjects treated with a therapeutic dose of NX-1207 had a mean percentage reduction in nocturia symptom score of 41% versus 4% for subjects treated with finasteride, an approved benign prostatic hyperplasia treatment. This improvement was statistically significant (p<.001).

In the study, subjects received a one-time single dose of NX-1207 administered by intraprostatic injection. The entire procedure lasted on average five minutes, with the injection taking one minute, and did not require anesthesia or catheterization. There were no significant side effects from NX-1207 in the trial.